Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194272 | 0.93 | EGFR (0.54) | EGFRFGFR1CCNA2CDK2CCNA1 | |
| SCHEMBL2196230 | 0.92 | FGFR1 (0.54) | EGFRFGFR1CCNA2CDK2CCNA1 | |
| SCHEMBL2194084 | 0.92 | CCNA2 (0.51) | EGFRFGFR1CCNA2CDK2CCNA1 | |
| SCHEMBL2194472 | 0.92 | EGFR (0.50) | EGFRFGFR1CCNA2CDK2CCNA1 | |
| SCHEMBL2196141 | 0.92 | EGFR (0.51) | EGFRFGFR1CCNA2CDK2CCNA1 | |
| SCHEMBL2196142 | 0.91 | CCNA2 (0.50) | EGFRFGFR1CCNA2CDK2CCNA1 | |
| SCHEMBL10274677 | 0.91 | EGFR (0.42) | EGFRFGFR1CCNA2CDK2CCNA1 | |
| SCHEMBL2195974 | 0.89 | CCNA2 (0.48) | EGFRFGFR1CCNA2CDK2CCNA1 | |
| SCHEMBL2194636 | 0.88 | EGFR (0.47) | EGFRFGFR1CCNA2CDK2CCNA1 | |
| SCHEMBL2087273 | 0.88 | EGFR (0.54) | EGFRFGFR1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172224-A1 | NOVEL HETEROCYCLES | CCNI, PCNA, CCNA1 | EGFR 2146/4885FGFR1 1058/4885CCNA2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.